Multidrug Idebenone/Naproxen Co-loaded Aspasomes for Significant in vivo Anti-inflammatory Activity

ChemMedChem. 2022 May 4;17(9):e202200067. doi: 10.1002/cmdc.202200067. Epub 2022 Mar 22.

Abstract

The use of proper nanocarriers for dermal and transdermal delivery of anti-inflammatory drugs recently gained several attentions in the scientific community because they pass intact and accumulate payloads in the deepest layers of skin tissue. Ascorbyl palmitate-based vesicles (aspasomes) can be considered a promising nanocarrier for dermal and transdermal delivery due to their skin whitening properties and suitable delivery of payloads through the skin. The aim of this study was the synthesis of multidrug Idebenone/naproxen co-loaded aspasomes for the development of an effective anti-inflammatory nanomedicine. Aspasomes had suitable physicochemical properties and were safe in vivo if topically applied on human healthy volunteers. Idebenone/naproxen co-loaded aspasomes demonstrated an increased therapeutic efficacy of payloads compared to the commercially available Naprosyn® gel, with a rapid decrease of chemical-induced erythema on human volunteers. These promising results strongly suggested a potential application of Idebenone/naproxen multidrug aspasomes for the development of an effective skin anti-inflammatory therapy.

Keywords: Aspasomes; anti-inflammatory properties; ascorbyl palmitate; multidrug nanocarriers and nanomedicine; topical drug delivery systems.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Naproxen* / metabolism
  • Naproxen* / pharmacology
  • Naproxen* / therapeutic use
  • Skin / metabolism
  • Skin Absorption*
  • Ubiquinone / analogs & derivatives

Substances

  • Anti-Inflammatory Agents
  • Ubiquinone
  • Naproxen
  • idebenone